...granted 510(k) clearance to include the use of 4 BD Bactec blood culture bottles for Microphage's...
...rights, markets the product in the U.S. The blood culture test has CE Mark approval. Microphage Inc....

...and has CE Mark approval (see BioCentury, May 16). Cardinal Health Inc. (NYSE:CAH), Dublin, Ohio MicroPhage Inc....

...FDA granted 510(k) clearance to Microphage's KeyPath MRSA/MSSA Blood Culture Test to identify Staphylococcus aureus bacteria...
...uses MicroPhage's bacteriophage amplification platform, is marketed outside the U.S. and has CE Mark approval. Microphage Inc....

...MicroPhage launched its Microphage MRSA/MSSA blood culture test outside the U.S. to identify Staphylococcus aureus bacteria...
...which uses MicroPhage's bacteriophage amplification platform and is already CE marked (see BioCentury, March 15). MicroPhage Inc....

...Business: Veterinary, Diagnostic, Supply/Service Hired: Steve Lundy as CEO and a director, formerly CEO of MicroPhage Inc....

...MicroPhage submitted a 510(k) application to FDA for its Microphage MRSA/MSSA blood culture test to identify...
...cases of bacteremia. The test, which uses MicroPhage's bacteriophage amplification platform, is already CE marked. Microphage Inc....

...aureus bacteria and determine methicillin resistance (MRSA) or susceptibility (MSSA) in suspected cases of bacteremia. Microphage...
...of the test in August designed to support a 510(k) application (see BioCentury, Aug. 31). Microphage Inc....

...a U.S. pivotal trial to evaluate its MRSA/MSSA blood culture test in about 700 patients. Microphage Inc....